看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。) }8 f) q n& q' g4 R' a0 t
/ i3 |9 p5 ?) s
* \1 ` c5 H4 C
Currently available feasibility data for possible combination strategies.
& a$ [* R5 Q. h* v————————————————————————————————
$ P* i E7 P! N0 a$ Y9 ^( ] }Combination Feasibility according to preliminary data 1 u, b5 I! v% b2 n( ^
——————————————————————————————————
% T! @0 G, {: `% P. U. V: Y# H0 oBevacizumab + sorafenib Yes, reduced dose + w2 B9 M2 }; h8 x. ?* y8 w
Bevacizumab + sunitinib† No : _. e/ F7 H0 F) w4 v% z
Bevacizumab + temsirolimus Yes
, l/ u, v0 j! D, NBevacizumab + everolimus Yes ' |8 z/ Y" x+ B" E* {
Sorafenib + sunitinib ? ( z% E+ f2 L8 Z! Y3 I' a
Sorafenib + temsirolimus Yes, reduced dose
p! b3 z* Y4 V. j3 s* c9 F- mSorafenib + everolimus Yes, reduced dose 1 I6 |6 u1 l% _4 a
Sunitinib + temsirolimus† No . u3 } z2 ^; N, K A
Sunitinib + everolimus ? % N* x& b& P" j
Temsirolimus + everolimus ?
% q( b8 H& ]0 ?( s0 ~————————————————————! b7 C" B- g: c7 T; R
†Led to US FDA warning.
1 P' a3 ^7 e2 ~* l2 u R8 W" x?: As yet unattempted combination.
# t) y' Y+ o, F* o0 I( W |